FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer

21st September 2021 Uncategorised 0

Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population

More: FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Source: News